http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories
-
Dyne Therapeutics to Present at Jefferies Healthcare Conference
-
Dyne Therapeutics (DYN) Granted EU Orphan Drug Designation for DYNE-101
-
Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-101
-
Dyne Therapeutics’ Preclinical Data Demonstrating FORCE™ Platform Delivery to CNS Featured in Oral Presentation at ASGCT Annual Meeting
-
Dyne Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
-
Dyne Therapeutics to Present at BofA Securities 2023 Healthcare Conference
-
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
-
Dyne Therapeutics to Present New Preclinical Data at ASGCT Annual Meeting Demonstrating FORCE™ Platform Delivery to CNS
-
Dyne Therapeutics Inc. (DYN) Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Receives FDA Orphan Drug and Rare Pediatric Designations for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics (DYN) Announces Presentations on its DM1 and DMD Programs
-
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
-
Dyne Therapeutics Announces Presentations on its DM1 and DMD Programs at the 2023 Muscular Dystrophy Association Clinical & Scientific Conference
-
Dyne Therapeutics to Present at Upcoming Investor Conferences
-
Dyne Therapeutics to Present at Upcoming Investor Conferences
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Dyne Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
-
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Dyne Therapeutics to Present at 41st Annual J.P. Morgan Healthcare Conference
-
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
-
Dyne Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
-
Dyne Therapeutics to Present at Investor Conferences in November
-
Dyne Therapeutics to Present at Investor Conferences in November
-
Dyne Therapeutics (DYN) Receives FDA Fast Track Designation for DYNE-251
-
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics (DYN) Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53
-
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
-
Dyne Therapeutics Presents Preclinical Data from its Duchenne Muscular Dystrophy Programs Targeting Exons 51 and 53 at World Muscle Society 2022 Congress
-
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
-
Dyne Therapeutics to Present at Chardan’s 6th Annual Genetic Medicines Conference
-
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
-
Dyne Therapeutics Highlights DM1 and DMD Clinical Programs During “Spotlight on the Clinic” Virtual Event
-
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
Dyne Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference
-
Dyne Therapeutics Inc. (DYN) Initiates Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 in DM1
-
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
-
Dyne Therapeutics Announces Initiation of Phase 1/2 ACHIEVE Clinical Trial of DYNE-101 for the Treatment of Myotonic Dystrophy Type 1
-
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Announces First Patient Dosed in Phase 1/2 DELIVER Clinical Trial of DYNE-251 for the Treatment of Duchenne Muscular Dystrophy
-
Dyne Therapeutics Inc. (DYN) Appoints Francesco Bibbiani as SVP and Head of Development
-
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
-
Dyne Therapeutics Appoints Francesco Bibbiani, M.D., as Senior Vice President, Head of Development
-
Dyne Therapeutics Inc. (DYN) Announces Publication of Preclinical Data
-
Dyne Therapeutics (DYN) Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
-
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
-
Dyne Therapeutics Announces “Breakthrough Article” Publication of Duchenne Muscular Dystrophy Program Data in Nucleic Acids Research
-
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
-
Dyne Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights
